Foundayo Hits Pharmacies as FDA Demands Additional Safety Data From Eli Lilly

The Second Oral GLP-1 Pill Launches Nationwide

Two weeks after FDA approval, Lilly began selling Foundayo last week, bringing the second oral GLP-1 weight loss medication to American pharmacies. The once-daily pill, containing the active ingredient orforglipron, offers a significant advantage over its competitor: while oral Wegovy must be taken on an empty stomach with a sip of water 30 minutes before any other medications or food and drink, Lilly's Foundayo can be taken at any time of day without food or water restrictions.

The launch represents a major milestone in GLP-1 access. Foundayo is available via LillyDirect, with prescriptions accepted immediately and shipping beginning April 6, followed shortly after by broad availability through U.S. retail pharmacies and telehealth providers.

For those who have struggled with the injection requirements of traditional GLP-1 medications, this oral option could open new possibilities for sustainable weight management.

Historic FDA Approval Process Raises Questions

The FDA approved Foundayo on April 1, marking the fifth approval under the Commissioner's National Priority Voucher pilot program and representing a historic milestone as the first new molecular entity approved under the program. The approval came 50 days after filing and 294 days before the application's standard review date.

Industry watchdogs and agency insiders have raised concerns that the pathway could undermine regulatory standards, particularly given the accelerated timeline. The controversial pathway, created in 2025, aims to expedite approval of applications that address critical national health priorities.

The rapid approval reflects the urgency around addressing America's obesity crisis, which affects over 100 million adults and drives hundreds of billions in healthcare costs annually.

FDA Demands Additional Safety Studies Post-Launch

Despite the rapid approval, the FDA is requiring Eli Lilly to conduct extensive post-marketing safety studies. A letter signed on April 1 said that Lilly must conduct post-marketing trials to assess risks of cardiovascular events and delayed gastric emptying. The FDA also asked Lilly to conduct a milk-only lactation study in women who have received a dose to assess concentrations of the drug in breast milk.

These requirements suggest the FDA wants more comprehensive safety data despite the accelerated approval process. The cardiovascular studies are particularly significant given that GLP-1 medications are being used by millions of Americans, many with existing heart disease risk factors.

The delayed gastric emptying studies address a known side effect of GLP-1 medications that can cause nausea and digestive issues. Understanding these risks better will help healthcare providers counsel their patients more effectively.

Pricing and Access: A More Affordable Option

Foundayo's pricing structure makes it more accessible than many injectable GLP-1 medications. Lilly is committed to making Foundayo accessible and affordable, with eligible people with commercial insurance paying as little as $25 per month with the Foundayo savings card, while individuals opting for self-pay can access Foundayo starting at $149 per month for the lowest dose.

The pricing represents a significant reduction compared to injectable GLP-1s, which can cost up to $1,000 monthly without insurance. Additionally, eligible Medicare Part D individuals may be able to get Foundayo for $50 per month, beginning as soon as July 1, 2026.

This more affordable pricing could make GLP-1 treatment accessible to many who have been priced out of injectable options. For a detailed breakdown of how these costs compare across different medications and insurance plans, check out our comprehensive cost guide.

Clinical Results Show Meaningful Weight Loss

In clinical trials, Foundayo demonstrated substantial weight loss results. At Week 72, people taking Foundayo 17.2 mg lost an average of 11.1% of body weight (25.2 lbs), compared with 8.3% (18.7 lbs) with Foundayo 9 mg, 7.4% (16.8 lbs) with Foundayo 5.5 mg, and 2.1% (4.8 lbs) with placebo.

While these results are promising, they're somewhat lower than the most effective injectable GLP-1 medications like semaglutide and tirzepatide. However, the emerging oral options are considered to be less effective than the injectables, but more convenient.

The trade-off between efficacy and convenience will be an important consideration for you and your healthcare provider when choosing the right treatment approach.

What This Means for You

If you've been considering GLP-1 treatment but hesitated due to injections or strict dosing requirements, Foundayo offers new flexibility. The ability to take it at any time without food restrictions could significantly improve your ability to stick with treatment compared to other oral options.

However, the FDA's requirement for additional safety studies means you should discuss the balance of benefits and risks with your healthcare provider. Consider your personal priorities: if maximum weight loss is your goal, injectable options might still be your best bet. If convenience and ease of use are more important, Foundayo could be worth exploring.

For those already on injectable GLP-1s, switching to Foundayo might make sense if convenience is a priority and you're achieving good results with your current medication. The lower cost compared to injectables could also make treatment more sustainable long-term.

To explore your options and find healthcare providers experienced with the full range of GLP-1 treatments, consider connecting with specialized clinics that can help you navigate this decision and manage any transition between medications.

Sources

1. FDA Approves First New Molecular Entity Under National Priority Voucher Program - FDA press release on Foundayo approval
2. FDA seeks added safety data from Lilly on weight-loss pill Foundayo - CNBC report on FDA safety requirements
3. FDA approves GLP-1 pill for obesity - Nature analysis of the approval and market implications
4. Foundayo Weight Loss Pill - Dosage, Cost, Side Effects - Comprehensive drug information and clinical trial data